Clover Health Investments CLOV

Reference table

1. What it is

Clover Health Investments (Nasdaq: CLOV) is a Medicare Advantage insurer. It sells PPO and HMO health plans to Medicare-eligible seniors, differentiated by its proprietary physician-facing software platform, the Clover Assistant, which surfaces patient data and care recommendations at the point of care with the goal of earlier diagnosis and lower medical cost. It also runs a small non-insurance software business (Counterpart Health, which licenses the Clover Assistant technology externally — its CEO appears in the insider filings). Founded 2014; listed 2020-06-12 (it came public via the Chamath Palihapitiya SPAC wave, a history that still shapes its retail-heavy shareholder base); headquartered in Franklin, TN; CEO Andrew Toy; ~570 employees.

Revenue mix: FMP's product- and geographic-segment blocks are empty for CLOV, so we cannot give a data-backed split — honestly flagged. From the income-statement shape, essentially all revenue is insurance premium revenue (cost of revenue = medical claims, running ~79% of revenue in Q1 2026), with the Counterpart Health software line not yet material enough to appear separately in this dataset.

2. The expert thesis — why the panel is bullish (traceable)

No expert-panel coverage — this note is fundamentals-driven. A search of the Synthos KB for CLOV returns zero claims: no bullish voices, no bearish voices, nothing to reconcile. That is the honest standard for a screen-surfaced name — CLOV entered the pipeline because a momentum screen flagged a +194% three-month move, not because anyone on the panel underwrote a thesis.

Practical consequences: (a) kb_breadth and kb_claim_count are 0 and conviction_rating is None; (b) both the bull and bear cases in §3 are built entirely from the company's filings, consensus estimates, and technicals in CLOV_data.json; and (c) the absence of any high-skill voice on a name this volatile is itself information — nobody credible in our pool has felt compelled to defend it at these prices.

3. Synthos scores & the Bull / Base / Bear cases

The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):

The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is the expected path, the cases bound the range.

Synthos fair value = the base case, ~$4.50 (−11%). Note what is unusual here: our base case, and the street's own consensus target, are below the market price. After a +194% three-month run the market is paying for the bull case up front. The range is wide (2.8× bull-to-bear) and asymmetric against the buyer at $5.06 — the honest read is that entry price, not the business, is the problem today. This is a tracked call — the Forecaster Scorecard grades it once it matures.

4. Exponential Potential

Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). CLOV is half of one:

• Forward growth: consensus revenue $1.92B (FY25 actual) → $2.91B (2026E, +51%) → $3.32B (2027E) → $3.67B (2028E) → $4.31B (2029E) → $4.80B (2030E). EPS $0.039 (2026E) → $0.051 → $0.125 → $0.21 → $0.28 (2030E) — a ~64% EPS CAGR off a near-zero base.
• Acceleration (the 2nd derivative) is negative after this year: +51% (2026E) → +14% (2027E) → +10% (2028E) → +18% (2029E) → +11% (2030E). The explosive year is the current one; the out-years are a low-teens grower on the consensus path. That is the opposite of the accelerating profile that earns an 8.
• Room to run: a $2.6B cap against the enormous Medicare Advantage market leaves plenty of theoretical room, and the Counterpart Health software-licensing line is genuine optionality (a SaaS multiple on even modest external revenue would matter at this size) — but that optionality is invisible in this dataset (no segment split) and cannot be underwritten yet.
• Estimate-quality caveat (important): the consensus is built on 1–2 analysts, and the estimate file is internally inconsistent — it shows positive net income every year 2026E–2030E alongside deeply negative EBITDA estimates (e.g. 2030E EBITDA −$824M vs net income +$145M), which cannot both be right. We treat the revenue and EPS lines as the usable signal and discard the EBITDA line as a data artifact. Thin, partly-garbled coverage is itself a risk flag.

Exponential Potential: Medium (5/10). Big percentage EPS growth from a tiny base, real TAM headroom, real software optionality — but decelerating revenue estimates, insurance-capped multiples, and coverage too thin to trust the out-years.

5. Financials (real numbers — FMP annual/quarterly)

• Revenue: FY25 $1.924B, +40.3% (FY24 $1.371B, +8.8% on FY23's $1.261B). The longer history is messy: FY21 revenue was $1.472B, FY22 $1.097B — the decline reflects the exit of the non-insurance/ACO-Reach-era business (FY22–24 income statements carry discontinued-operations lines). The clean story starts ~FY23.
• Quarterly trajectory (the inflection): Q1'25 $462M (net −$1.3M) → Q2'25 $478M (−$10.6M) → Q3'25 $497M (−$24.4M) → Q4'25 $488M (−$49.3M) → Q1'26 $749M (+62.0% YoY), net income +$27.3M, diluted EPS $0.0513. The Q1 revenue step-change is the 2026 plan-year membership cohort landing. Note the deterioration through 2025 (Q4 was the worst loss of the year) before the Q1 snap — margins here are lumpy and seasonal (Q1 is seasonally the lightest-cost quarter for MA insurers). Data caveat: FMP's Q4'25 expense mapping is garbled (G&A shown as −$140M against a $264M "other expenses" line); the net-loss figure of −$49.3M is the reliable number.
• Margins: gross margin 18.4% TTM (Q1'26: 21.3% — cost of revenue, i.e. medical costs, at 78.7% of premium revenue); operating and net margin −2.6% TTM, +3.6% in Q1'26. FY25 operating loss −$85.5M / EPS −$0.17.
• Cash flow: FY25 operating CF −$66.9M, FCF −$69.0M (capex is trivial, ~$2M — asset-light). FY24 was OCF-positive (+$34.8M), so cash generation has oscillated around zero. On a TTM basis (including the strong Q1'26) FCF is positive ~$54.5M (FCF yield ~2.1%) — but insurance cash flow is premium-timing-driven; do not annualize one Q1.
• Stock comp: $103.7M in FY25 — 5.4% of revenue against a company that lost $85.5M; SBC/revenue is 4.0% TTM. Share count grew from 470M (FY21) to 522M (Q1'26) despite buybacks.
• Balance sheet (the genuine strength): zero debt. Cash + short-term investments $95.3M plus $187.1M long-term investments = ~$282M against total equity of $308.7M; total assets $541M. Retained deficit −$2.29B tells the history. Current ratio 1.33 TTM.

6. Valuation — priced in or room?

There is no earnings anchor yet: TTM EPS is −$0.11 (trailing P/E meaningless at −45×). What the market is paying: P/S 1.19× / EV/S 1.11× on TTM revenue, 7.8× book, and on the thin forward consensus 131× 2026E EPS ($0.039) → 100× 2027E → 40× 2028E → 24× 2029E → 18× 2030E. To buy at $5.06 you must underwrite the 2029–2030 earnings of a company with one profitable quarter, estimated by 1–2 analysts. For context, FMP's letter rating is C− (overall score 1/5; DCF, ROE, ROA, and P/E component scores all 1/5). Street targets: consensus $4.47 (median $4.475, high $4.75, low $4.20) — the entire analyst range sits below the market price, and the rating mix is 1 Buy / 5 Hold / 3 Sell (consensus: Hold). An EV/S of ~1.1× is not absurd for a growing insurer with net cash — the multiple is not the issue; the issue is that the price has front-run every published estimate of fair value, including ours.

7. Technicals (from the tech block)

• Trend: violently up. $5.06 sits +29% above the 50-DMA ($3.91) and +79% above the 200-DMA ($2.82); MACD +0.41 (positive).
• Location: −6.5% off the 52-week high ($5.41) and +198% off the 52-week low ($1.70) — pressed against its highs after a vertical run. The all-time context matters more: max drawdown from peak is −77% (the 2021 meme-era high near $22 was never revisited).
• Momentum: RSI(14) 59 — elevated but not technically overbought; the price action has consolidated the spike rather than gone parabolic-and-reversed.
• Relative strength (the tell): +194% over 3 months vs SPY +14.6% / QQQ +23.6%; +115% 6-mo; +95% 12-mo vs SPY +21.1% / QQQ +31.2%. Essentially all of the 12-month gain happened in the last quarter — this is a momentum spike, not a steady accumulation.
• Read: technically extended. Chasing a stock 29% above its 50-DMA after a 3× quarter, with insiders selling into it, is poor risk/reward; the constructive setup is a retest of the rising 50-DMA (~$3.90) that holds — which is exactly our watch trigger.

8. Moat & competitive position

The claimed moat is the Clover Assistant: if software-driven early diagnosis structurally lowers medical cost ratios, Clover earns an underwriting edge that scales with membership, and Counterpart Health can license it to other payers/providers — a software margin layered on an insurance book. Q1 2026 (medical costs 78.7% of premiums, positive net income) is the first quarterly evidence the model can clear its cost structure. But the honest counterweights: one quarter proves little in a business where costs arrive with a lag; the competition is UnitedHealth, Humana, CVS/Aetna and Elevance — giants with actuarial depth, provider networks and rate-negotiation scale Clover cannot match at 570 employees; MA is a regulated, politically exposed market (CMS rate notices and risk-adjustment audits move the whole sector); and switching costs accrue to incumbents. ROIC of −16% TTM says no economic moat is visible in the numbers yet.

Peer set (FMP-supplied, market cap): the supplied list is essentially useless as a comp set — BGM Group $76M, Certara $1.1B, Structure Therapeutics $3.2B, Guardian Pharmacy $2.6B, LifeStance $4.3B, National HealthCare $3.4B, PROCEPT BioRobotics $1.2B, QuidelOrtho $1.2B, Twist Bioscience $6.2B, 10x Genomics $5.1B. Not one is a Medicare Advantage insurer. The relevant comparators (UNH, HUM, ALHC, CVS/Aetna) are absent — a data caveat: judge CLOV against the MA payer cohort, where healthy insurers trade at a fraction of CLOV's 7.8× book.

9. Management, capital allocation & guidance

• Capital allocation: FY25 saw $55.2M of buybacks while operating cash flow was −$66.9M — repurchasing shares with balance-sheet cash during a cash-burn year is aggressive, and it only partly offset $103.7M of stock comp (net share count still rose). No dividend, no debt. Capex ~$2M/yr — asset-light by construction.
• Insider activity (the loudest signal in the file): the recent Form 4 record is uniformly sales, across the whole executive suite, into the rally: CEO Andrew Toy sold 313,476 shares at $5.32 on 2026-07-01; Counterpart Health CEO Conrad Wai sold 220,426 at $3.99 (2026-05-28); Medicare Advantage CEO Jamie Reynoso sold on four separate dates in June–July ($4.61–$5.26); the Chief Legal Officer and VP Finance/Controller also sold in June. Some of this is routine 10b5-1 diversification and the individual amounts are modest versus holdings (Toy still reports ~9.6M shares) — but there is not a single purchase in the block, and the CEO's sale is the largest and the most recent. On a stock trading above the street target, that is a meaningful negative tell.
• Management guidance: no company guidance is present in this dataset, and there are no management claims in the KB to half-weight. The only forward markers we can cite are the consensus rows: Q2 2026 (reports 2026-08-04) Street EPS $0.05 on revenue ~$728M. Track record note from the earnings calendar: Q1'26 met the $0.07 EPS estimate on a revenue beat ($749M vs $715M est.); Q3'25 badly missed (−$0.05 vs +$0.02 est.) — estimate reliability here is low in both directions.

10. Catalysts & what to watch

• Next earnings: 2026-08-04 (Q2 2026; Street EPS $0.05, revenue ~$728M). The key line is medical costs as % of premium revenue — Q1's 78.7% is the number that must hold as the year's cost seasonality builds. Recall 2025's pattern: profitable-ish Q1/Q2, then escalating losses in Q3/Q4. A repeat kills the thesis.
• Membership/enrollment disclosures: the +62% revenue jump is the 2026 cohort; watch whether growth came with adverse selection (new members are typically costlier in year one).
• CMS policy cycle: the 2027 MA rate notice and any risk-adjustment (RADV) audit developments — sector-wide, and outsized for a single-state-concentrated small carrier.
• Counterpart Health: any disclosed external licensing deal would create the software segment this dataset can't yet see — the main bull-case optionality.
• Insider filings: more C-suite selling at these prices, or a first insider buy, would each be signal.

Thesis tripwires (what would change the call): Q2 medical-cost ratio deteriorating materially from ~79%; a return to operating losses in H2 2026; a large equity raise (the SBC run-rate already dilutes ~4%/yr); or — on the positive side — a held retest of ~$3.90 plus a second consecutive profitable quarter, which would justify re-scoring toward a Tactical buy.

11. Key risks

• Medical-cost reversion (the dominant risk): the entire MA industry has been fighting elevated utilization; Clover's profit cushion is one quarter and ~$27M deep. A 2-point rise in the medical-cost ratio (~79% in Q1) roughly erases quarterly profitability.
• Entry-price / momentum risk: +194% in 3 months, price above the street's high target ($4.75), beta 2.42, and a retail-heavy register with meme history — the stock can halve without the fundamentals changing at all (it has done far worse before: max drawdown −77%).
• Insider selling: uniform executive selling into the rally, including the CEO on 2026-07-01 at $5.32.
• Coverage and estimate quality: 1–2 analysts, internally inconsistent estimate file (positive net income, deeply negative EBITDA in the same rows) — the forward "consensus" is a thin reed.
• Regulatory / concentration: CMS rate-setting, risk-adjustment audits, and star-ratings swings hit small, geographically concentrated MA plans hardest.
• Scale disadvantage: 570 employees versus UNH/Humana-class competitors in a business where scale sets unit costs and network rates.
• Dilution: SBC at 4% of revenue with the share count grinding higher despite buybacks.

12. Verdict, position sizing & monitoring

Watch. The Q1 2026 print is the most important quarter in Clover's public life — +62% revenue growth, a real $27.3M GAAP profit, positive TTM free cash flow, zero debt, and ~$282M of cash and investments. The turnaround is no longer hypothetical. But everything about the price argues for patience: the stock tripled in a quarter, trades 11% above our $4.50 base case and above the street's entire target range ($4.20–$4.75), carries 3 Sell ratings out of 9, and the executive suite — including the CEO — has been selling into the move. With zero expert-panel coverage to lean on and a one-quarter-old margin inflection, buying at $5.06 is paying the bull case up front.

• Sizing: 0% today — watchlist. If the trigger hits (a held pullback toward the ~$3.90 50-DMA and a Q2 print on 2026-08-04 that keeps medical costs near ~79% and EPS ≥ the $0.05 estimate), re-score toward a speculative Tactical buy at max ~0.5–1% of the flagship — sized for a 2.42-beta name with a −77% drawdown history.
• Monitoring: re-underwrite on the §10 tripwires; formal re-score at the 2026-08-04 print. This verdict is logged as a tracked Synthos call as of 2026-07-06 at $5.06.
• Single biggest risk: a Medicare Advantage medical-cost spike erasing a one-quarter-old profit — on a momentum stock already priced above the street's own fair-value estimates.

Provenance & disclosures

• Traceability: 0 KB claims, 0 voices — a search of the labeled expert KB returns no CLOV coverage, so this note is fundamentals-driven by declaration, not omission. kb_net_conviction is null and conviction_rating is None rather than invented. Fabricated conviction is structurally impossible (claim-ID reconciliation).
• Data as-of: fundamentals 2026-03-31 (Q1 2026, filed 2026-05-08) · estimates & prices 2026-07-06 · insider filings through 2026-07-06. All figures from the FMP data file (CLOV_data.json); forward figures are analyst consensus, labeled as estimates.
• Estimate caveat: consensus is built on 1–2 analysts and the estimate rows are internally inconsistent (positive net income alongside deeply negative EBITDA 2026E–2030E); we use the revenue/EPS lines and discard the EBITDA line as an artifact.
• Data caveats: FMP segment data (product and geography) is empty for CLOV; the Q4 2025 expense mapping is garbled (net loss of −$49.3M is the reliable line); the FMP-supplied peer list contains no Medicare Advantage insurers — judge against the MA payer cohort (UNH, HUM, ALHC, CVS) instead.
• DCF/multiple assumptions are ours and labeled: base = ~35× 2028E EPS of $0.125; bull = ~25× 2030E EPS of $0.28; bear = ~0.45× 2026E sales per share. The street's $4.47 consensus target is reported as context and happens to coincide with our base case.
• Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
• Version: 2026-07-06. Prior versions available via the deep-dive version dropdown ("based on the info at the time").